DOI QR코드

DOI QR Code

제약회사의 현금흐름이 연구개발투자에 미치는 영향 -코스닥시장을 중심으로

Effect of Cash flow on the R&D investment of Pharmaceutical Companies - focused on KOSDAQ market

  • 이문재 (고려대학교 보건정책관리학부/보건과학연구소) ;
  • 최만규 (고려대학교 보건정책관리학부.대학원 보건과학과/BK21PLUS 인간생명-사회환경 상호작용 융합사업단)
  • 투고 : 2015.06.25
  • 심사 : 2015.07.08
  • 발행 : 2015.08.28

초록

본 연구는 우리나라 코스닥 제약회사를 대상으로 내 외부금융이 연구개발투자(R&D)에 미치는 영향을 분석하였다. 실증분석을 위한 표본은 2009년부터 2013년까지 상장된 기업들 중 코스닥 제약회사를 대상으로 하였으며 사용된 전체 표본은 5개년 자료로써 212개 관측치를 가진 불균형패널자료이다. 본 연구에 사용된 주요 변수들 중 개별기업 별 재무자료는 상장회사 협의회의 TS-2000, 금융감독원 전자공시 시스템의 각 기업 사업보고서, NICE신용평가정보의 KISVALUE-III 등의 자료를 통해 직접 수집하였으며, 패널분석을 위해 STATA 12.0을 사용하였다. 연구결과, 첫째 내부금융(유동비율)은 연구개발투자에 긍정적인 영향을 미쳤다. 둘째, 외부금융(부채비율)은 연구개발투자에 부정적인 영향을 미쳤다. 본 연구는 자본시장에서 정보의 비대칭으로 인해 외부금융보다 내부금융이 더 선호됨을 알 수 있다. 즉, 제약기업의 연구개발투자 활성화를 위해 내부금융의 관리 및 정부의 정책적 지원이 필요함을 보여준다.

키워드

제약회사;연구개발투자;현금흐름;내부금융;외부금융

참고문헌

  1. K. Arrow, "Economic welfare and the allocation of resources for invention, The rate and direction of inventive activity," Economic and social factors, pp.609-626, 1962.
  2. M. I. Kamien and N. L. Schwartz, "Self-Financing of an R and D Project," The American Economic Review, Vol.68, No.3, pp.252-261, 1978
  3. J. E. Stiglitz and A. Weiss, "Credit rationing in markets with imperfect information," The American economic review, Vol.71, No.3, pp.393-410, 1981
  4. S. C. Myers and N. S. Majluf, "Corporate financing and investment decisions when firms have information that investors do not have," Journal of financial economics, Vol.13, No.2, pp.187-22, 1984 https://doi.org/10.1016/0304-405X(84)90023-0
  5. S. Fazzari, R. G. Hubbard, and B. C. Petersen, "Financing constraints and corporate investment," National Bureau of Economic Research Cambridge, Mass., USA; 1988.
  6. D. R. Shin, "A Study on the Impact of Information Asymmetry on the Financial Structure of Korean Manufacturing Firms," Asian Review of Financial Research, Vol.5, pp.77-102, 1992.
  7. S. Y. Cho, S. W. Shin, and W. H. Lee, "The Impact of Financial Leverage on Firm Investment: Listed Manufacturing firm's Data for System-GMM Panel Analysis," Public Finance Forum, Vol.10, No.2, pp.41-74, 2004.
  8. M. Lee and M. Choi, "Analysis of Structural Relationships among Financial ratios of Regional Public Hospitals," Korean Journal of Business Administration, Vol.26, No.6, pp.1517-1530, 2013
  9. C. W. Hill and S. A. Snell, "External control, corporate strategy, and firm performance in research‐intensive industries," Strategic Management Journal, Vol.9, No.6, pp.577-590, 1988. https://doi.org/10.1002/smj.4250090605
  10. B. Baysinger and R. E. Hoskisson, "The composition of boards of directors and strategic control: Effects on corporate strategy," Academy of Management Review, Vol.15, No.1, pp.72-87, 1990.
  11. R. Kochhar and P. David, "Institutional investors and firm innovation: A test of competing hypotheses," Strategic Management Journal, Vol.17, No.1, pp.73-84, 1996. https://doi.org/10.1002/(SICI)1097-0266(199601)17:1<73::AID-SMJ795>3.0.CO;2-N
  12. P. David, M. A. Hitt, and J. Gimeno, "The influence of activism by institutional investors on R&D," Academy of Management Journal, Vol.44, No.1, pp.144-157, 2001. https://doi.org/10.2307/3069342
  13. R. E. Hoskisson, M. A. Hitt, R, A. Johnson, and W. Grossman, "Conflicting voices: The effects of institutional ownership heterogeneity and internal governance on corporate innovation strategies," Academy of Management Journal, Vol.25, No.4, pp.697-716, 2002.
  14. J. H. Choi, "The Effect of Advertising and Research and Development Expenditures on the Firm Value: An Empitical Analysis by Tobin's Q," Korean Accounting Review, Vol.19, No.1, pp.103-124, 1994.
  15. M. Lee, "Impact of corporate governance on research & development investment in the pharmaceutical industry in South Korea," Osong Public Health And Research Perspectives, doi: 10.1016/j.phrp.2015.07.003, 2015 https://doi.org/10.1016/j.phrp.2015.07.003
  16. H. G. Grabowski and J. Vernon, "The distribution of sales revenues from pharmaceutical innovation," Pharmacoeconomics, Vol.19, No.1, pp.21-32, 2000.
  17. JA. Vernon, "Examining the link between price regulation and pharmaceutical R&D investment," Health economics, Vol.14, No.1, pp.1-16, 2005. https://doi.org/10.1002/hec.897
  18. C. P. Himmelberg and B. C. Petersen, "R & D and internal finance: A panel study of small firms in high-tech industries," The Review of Economics and Statistics, pp.38-51, 1994.
  19. S. Bhagat and I. Welch, "Corporate research & development investments international comparisons," Journal of Accounting and Economics, Vol.19, No.2, pp.443-470, 1995. https://doi.org/10.1016/0165-4101(94)00391-H
  20. M. Lee and M. Choi, "The relationship between R&D investment and ownership structure in KOSDAQ pharmaceutical firms," Journal of the Korea Contents Association, Vol.15, No.6, pp.:445-54, 2015
  21. B. H. Hall, "Investment and research and development at the firm level: does the source of financing matter?," National Bureau of Economic Research, 1992.
  22. M. Lee and M, Choi, "Analysis on time lag effect of R&D investment in the pharmaceutical industry in Korea," Osong Public Health And Research Perspectives, doi: 10.1016/j.phrp.2015.07.001, 2015 https://doi.org/10.1016/j.phrp.2015.07.001